Top

Published in:

Open Access 01-12-2015 | Letter to the Editor

Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K562 cells

Authors: Sichu Liu, Qi Shen, Yu Chen, Chengwu Zeng, Changshu Cao, Lijian Yang, Shaohua Chen, Xiuli Wu, Bo Li, Yangqiu Li

Published in: Journal of Hematology & Oncology | Issue 1/2015

Abstract

We reported that knockdown of PPP2R5C by siRNA led to proliferation inhibition and apoptosis induction in K562 cells. In this study, we further characterized the gene expression profiles after PPP2R5C suppression by microarray analysis. Genes which participate in the MAPK, PI3K/AKT, and JAK/STAT pathways, were mainly altered in the K562 cells. We propose that the mechanism for proliferation inhibition and increased apoptosis of K562 cells following PPP2R5C suppression may be related to the alteration of expression profiles of BRAF, AKT2, AKT3, NFKB2 and STAT3 genes.

Available only for authorised users

Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, et al. Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol. 2011;4:21.CrossRefPubMedCentralPubMed

Shen Q, Liu S, Chen Y, Yang L, Chen S, Wu X, et al. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol. 2013;6:64.CrossRefPubMedCentralPubMed

Chen Y, Liu S, Shen Q, Zha X, Zheng H, Yang L, et al. Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells. DNA Cell Biol. 2013;32:573–81.CrossRefPubMedCentralPubMed

Zha X, Chen S, Yang L, Shi L, Li B, Wu X, et al. Upregulated TCRzeta enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012;31:1628–35.CrossRefPubMedCentralPubMed

Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013;6:54.CrossRefPubMedCentralPubMed

Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. J Hematol Oncol. 2014;7:37.CrossRefPubMedCentralPubMed

Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18:930–7.CrossRefPubMed

De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17–27.CrossRefPubMed

Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK, Los M. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL–an alternative approach to conventional rational drug design. PLoS One. 2012;7:e28395.CrossRefPubMedCentralPubMed

10.

Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82–5.CrossRefPubMed

11.

Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98:11598–603.CrossRefPubMedCentralPubMed

12.

Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005–14.CrossRefPubMedCentralPubMed

13.

Shouse GP, Cai X, Liu X. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008;28:448–56.CrossRefPubMedCentralPubMed

14.

Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6:23.CrossRefPubMedCentralPubMed

Title: Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K562 cells
Authors: Sichu Liu
Qi Shen
Yu Chen
Chengwu Zeng
Changshu Cao
Lijian Yang
Shaohua Chen
Xiuli Wu
Bo Li
Yangqiu Li
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-015-0125-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Drugging the unfolded protein response in acute leukemias

Platelet functional alterations in a Bernard-Soulier syndrome patient with filamin A mutation

Zebrafish as a model for leukemia and other hematopoietic disorders

Endothelial progenitor cells in ischemic stroke: an exploration from hypothesis to therapy

Role of DNA methylation in renal cell carcinoma

Transfer of microRNAs by extracellular membrane microvesicles: a nascent crosstalk model in tumor pathogenesis, especially tumor cell-microenvironment interactions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer